Pharvaris N.V.
deucrictibant
hereditary angioedema (HAE)
Resolved
126days ago
Catalyst readout · Jun 30, 2026
What's at stake
A key catalyst for deucrictibant (hereditary angioedema (HAE)) is expected Jun 30, 2026.
Primary source
· SEC 6-K
verified 4mo ago
“Submission of U.S. New Drug Application (NDA) of deucrictibant IR for the on-demand treatment of HAE attacks anticipated 1H2026.”